GlassScriptPhysician profile
Joyce Awujor
NPI 1063119832
$4,858.04
in general payments reported to CMS, 2019-2025
20 companies · $2,246 in 2025
The $2,246 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $577 · 2024: $2,036 · 2025: $2,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,846 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,845.89 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $748.07 | 2023-2025 | Caplyta |
| Abbvie INC. | $687.41 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $415.88 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $381.11 | 2023-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Lundbeck LLC | $373.87 | 2023-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $319.45 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $300.29 | 2023-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $279.18 | 2024-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $263.50 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Axsome Therapeutics, INC. | $172.16 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $155.42 | 2025 | Cobenfy |
| Corium, LLC | $155.14 | 2023-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $146.97 | 2023-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $114.74 | 2023-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $89.98 | 2023-2024 | Trintellix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $85.17 | 2024-2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $74.90 | 2023-2025 | Quviviq, Quviviq |
| Collegium Pharmaceutical, INC. | $53.87 | 2025 | Jornay Pm |
| Janssen Scientific Affairs, LLC | $26.45 | 2025 | Invega Sustenna |
| Tris Pharma INC | $14.48 | 2024 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Awujor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.